Evidence map›Paper›PMID 32448633›Full record

ReviewSemergen2020

[COVID-19 and cardiovascular and kidney disease: Where are we? Where are we going?]

V Pallarés Carratalá, C Górriz-Zambrano, C Morillas Ariño, J L Llisterri Caro, J L Gorriz

Abstract readReview
In one paragraph

Review in Semergen, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

V Pallarés CarrataláMedicina Familiar y Comunitaria, Unidad de Vigilancia de la Salud, Unión de Mutuas, Castellón, España; Departamento de Medicina, Facultad de Ciencias de la Salud, Universitat JaumeI, Castellón, España. Electronic address: pallares.vic@gmail.com.
C Górriz-ZambranoMedicina Familiar y Comunitaria, CAP Sant Pere, ABS Reus1, Reus, Tarragona, España.
C Morillas AriñoServicio de Endocrinología, Hospital Universitario Dr. Peset, Valencia, España; Departamento de Medicina, Facultad de Medicina, Universitat de València, Valencia, España.
J L Llisterri CaroMedicina Familiar y Comunitaria, Fundación de Investigación SEMERGEN (Madrid), Clínica Vallada, Valencia, España.
J L GorrizDepartamento de Medicina, Facultad de Medicina, Universitat de València, Valencia, España; Servicio de Nefrología, Hospital Clínico Universitario de Valencia, INCLIVA, Valencia, España.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-CoV-2 pandemic is a global health emergency and we need to know more about it. Patients with cardiovascular risk and previous kidney risk have been identified as especially vulnerable for greater morbidity and mortality when they suffer from COVID-19. A considerable proportion of patients can develop a vascular lesion in the context of the disease that entails a greater lethality. Cardiovascular and renal complications represent a problem and, probably in the near future, may pose a threat to patients who have survived COVID-19. As physicians, we cannot forget that during an epidemic like this, other chronic diseases are present, and patients continue to require care. We are obliged to monitor even more intensely their treatments and control degree. Furthermore, we must not forget that urgent situations continue to arise in this pandemic situation and require prompt attention. In this current situation, it is very likely that many patients, out of fear, have not sought medical attention. The situation during the epidemic and the uncertainty of the post-COVID-19 period, requires intensification in the control and monitoring of cardiovascular and kidney disease in our patients. Primary care constitutes a key level of care for the care of the population with cardiovascular disease. Likewise, and in the face of this new health scenario, we need to promote the prevention and control measures that emanate from the studies currently underway. Now, more than ever, we need research, crucial to improve the cardiovascular and renal prognosis of our patients.

Indexed as

Cardiovascular DiseasesCoronavirus InfectionsKidney DiseasesPandemicsPneumonia, ViralCOVID-19Diabetes ComplicationsDyslipidemiasHumansRisk FactorsCardiovascular diseaseChronic kidney diseaseCOVID-19Enfermedad cardiovascularEnfermedad renal crónicaMorbidityMorbilidadMortalidadMortality

Identifiers

PMID32448633
PMCPMC7211659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.